Antimicrobial use for the treatment of bacterial sexually transmitted infections among doxycycline post-exposure prophylaxis (DoxyPEP) users in Milan, Italy
Journal of Antimicrobial Chemotherapy · 2025
DOI: 10.1093/jac/dkaf244 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2025. Verfasst von Angelo Roberto Raccagni und 10 weiteren Autor:innen. Beteiligte Einrichtung: Infectious Diseases Unit, Vita-Salute San Raffaele University, Milan, Italy. Hauptthemen laut MEDLINE: Doxycycline, Post-Exposure Prophylaxis, Anti-Bacterial Agents, Sexually Transmitted Diseases, Bacterial. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 10 Literaturangaben.
Abstract (Originalsprache)
Background
Doxycycline post-exposure prophylaxis (DoxyPEP) is effective in reducing bacterial sexually transmitted infections (bSTIs) among MSM.
Objectives
The aim of this study is to evaluate whether DoxyPEP introduction is associated with subsequent reduction of antimicrobial use among MSM.
Methods
This is a retrospective study of MSM at the San Raffaele Hospital, Italy, who received DoxyPEP prescription from August 2022 to July 2024. DoxyPEP was suggested for intensive sexual activity (>5 partners). Adjusted %changes in incidence rate of bSTIs before and after DoxyPEP prescription were estimated using a pre-post within-person analysis by Poisson mixed-effects model. Use of DoxyPEP and ceftriaxone, benzylpenicillin and doxycycline for bSTI treatment was quantified as days of therapy (DOTs) per 1000 person-days (1000-PD). The observed DOTs after DoxyPEP prescription were increased with %changes derived from regressions to obtain the expected DOTs in absence of DoxyPEP.
Results
Overall, 754 MSM were prescribed DoxyPEP; during follow-up, 222 (29.4%) reported using DoxyPEP. Median follow-up among DoxyPEP users were 15.8 months (IQR = 12.1–19.2) and 10.8 (6.88–13.1) before and after prescription, respectively. Among DoxyPEP users, 401 bSTIs (Tp 70, Ct 139, Ng 192) were detected before prescription and 146 (Tp 26, Ct 32, Ng 88) after. DOT per 1000-PD was 1.26 for ceftriaxone, 0.37 for penicillin and 3.21 for doxycycline after prescription; DoxyPEP DOT per 1000-PD was 7.00. Expected DOT in the absence of DoxyPEP was 4.85 (95% CI = 3.82–6.41) for ceftriaxone, 1.86 (95% CI = 1.17–2.87) for penicillin and 24.71 (95% CI = 17.18–37.36) for doxycycline.
Conclusions
A significant reduction in antibiotics used for the treatment of bSTIs was achieved among DoxyPEP users.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Infectious Diseases Unit, Vita-Salute San Raffaele University, Milan, Italy.
- Infectious Diseases Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy.
ORCID-Profile: Angelo Roberto Raccagni, Giacomo Ponta, Camilla Muccini, Silvia Nozza
Zitieren
APA
Raccagni, A. R., Diotallevi, S., Lolatto, R., Bruzzesi, E., Badalucco Ciotta, F., Ponta, G., Passini, F., Candela, C., Muccini, C., Castagna, A., & Nozza, S. (2025). Antimicrobial use for the treatment of bacterial sexually transmitted infections among doxycycline post-exposure prophylaxis (DoxyPEP) users in Milan, Italy. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkaf244
Vancouver
Raccagni AR, Diotallevi S, Lolatto R, Bruzzesi E, Badalucco Ciotta F, Ponta G, et al. Antimicrobial use for the treatment of bacterial sexually transmitted infections among doxycycline post-exposure prophylaxis (DoxyPEP) users in Milan, Italy. Journal of Antimicrobial Chemotherapy. 2025. doi:10.1093/jac/dkaf244
BibTeX
@article{Raccagni2025,
author = {Raccagni, Angelo Roberto and Diotallevi, Sara and Lolatto, Riccardo and Bruzzesi, Elena and Badalucco Ciotta, Flavia and Ponta, Giacomo and Passini, Flavia and Candela, Caterina and Muccini, Camilla and Castagna, Antonella and Nozza, Silvia},
title = {Antimicrobial use for the treatment of bacterial sexually transmitted infections among doxycycline post-exposure prophylaxis (DoxyPEP) users in Milan, Italy},
journal = {Journal of Antimicrobial Chemotherapy},
year = {2025},
doi = {10.1093/jac/dkaf244}
}
EUVIMED